Roth Capital Reiterates $32 PT on Stemline Therapeutics (STML) as Breakthrough Therapy Granted

Roth Capital analyst Joseph Pantginis reiterated a Buy rating and $32 price target on Stemline Therapeutics (NASDAQ: STML) after the company announced the FDA has granted Breakthrough Therapy Designation to SL-401 for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Pantginis notes, presently, no standards of care exist in both the front-line and relapsed/refractory settings for BPDCN.

Pantginis commented, "We believe that this is a major step forward for STML and SL-401 and look toward further updates later this year, including ASH."

For an analyst ratings summary and ratings history on Stemline Therapeutics click here. For more ratings news on Stemline Therapeutics click here.

Shares of Stemline Therapeutics closed at $7.40 yesterday.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Tesla (TSLA) soars on Q1 print
• Acrivon Therapeutics Inc (ACRV) PT Lowered to $22 at Jones Trading